Landscape of CDKN1B Mutations in Luminal Breast Cancer and Other Hormone-Driven Human Tumors

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2018 Aug 2

PMID 30065701

Citations 20

Authors

Martina Cusan

Giorgia Mungo

Mara De Marco Zompit

Ilenia Segatto

Barbara Belletti

Gustavo Baldassarre

Affiliations

Soon will be listed here.

Abstract

The gene encodes for the p27 protein, firstly characterized as a cyclin dependent kinase (CDK)-inhibitor. Germline pathogenic variants have been described in hereditary tumors, such as multiple endocrine neoplasia (MEN)-like syndromes and familial prostate cancer. Despite its central role in tumor progression, for a long time it has been proposed that was very rarely somatically mutated in human cancer and that its expression levels were almost exclusively regulated at post-transcriptional level. Yet, the advent of massive parallel sequencing has partially subverted this general understanding demonstrating that, at least in some types of cancer, is mutated in a significant percentage of analyzed samples. Recent works have demonstrated that can be genetically inactivated and this occurs particularly in sporadic luminal breast cancer, prostate cancer and small intestine neuroendocrine tumors. However, a clear picture of the extent and significance of mutations in human malignances is still lacking. To fill this gap, we interrogated the COSMIC, ICGC, cBioPortal, and TRANSFAC data portals and current literature in PubMed, and reviewed the mutational spectrum of in human cancers, interpreting the possible impact of these mutations on p27 protein function and tumor onset and progression.

Citing Articles

Neuroendocrine Tumors: Germline Genetics and Hereditary Syndromes.

Lauricella E, Chaoul N, DAngelo G, Giglio A, Cafiero C, Porta C Curr Treat Options Oncol. 2025; 26(1):55-71.

PMID: 39821711 DOI: 10.1007/s11864-024-01288-z.

Targeting CDK2 to combat drug resistance in cancer therapy.

Kasirzadeh S, Lenjisa J, Wang S Future Oncol. 2024; 20(39):3325-3341.

PMID: 39469865 PMC: 11633421. DOI: 10.1080/14796694.2024.2416382.

Childhood Multiple Endocrine Neoplasia (MEN) Syndromes: Genetics, Clinical Heterogeneity and Modifying Genes.

Lanzaro F, De Biasio D, Cesaro F, Stampone E, Tartaglione I, Casale M J Clin Med. 2024; 13(18).

PMID: 39336996 PMC: 11432259. DOI: 10.3390/jcm13185510.

A toxicogenomics-based identification of potential mechanisms and signaling pathways involved in PFCs-induced cancer in human.

Dehghani Z, Ranjbar S, Shahabinezhad F, Sabouri P, Mohammadi Bardbori A Toxicol Res (Camb). 2024; 13(5):tfae151.

PMID: 39323479 PMC: 11420517. DOI: 10.1093/toxres/tfae151.

G2/M Checkpoint Modulation: Insights from miRNA Profiles in FAM and Breast Cancer.

Haryana S, Ardiansyah S, Noficandra H, Wardana T, Sesotyosari S, Arfira F Asian Pac J Cancer Prev. 2024; 25(8):2661-2668.

PMID: 39205563 PMC: 11495450. DOI: 10.31557/APJCP.2024.25.8.2661.

References

Bugalho M, Domingues R . Uncommon association of cerebral meningioma, parathyroid adenoma and papillary thyroid carcinoma in a patient harbouring a rare germline variant in the CDKN1B gene. BMJ Case Rep. 2016; 2016. PMC: 4716429. DOI: 10.1136/bcr-2015-213934. View

Schiappacassi M, Lovisa S, Lovat F, Fabris L, Colombatti A, Belletti B . Role of T198 modification in the regulation of p27(Kip1) protein stability and function. PLoS One. 2011; 6(3):e17673. PMC: 3056717. DOI: 10.1371/journal.pone.0017673. View

Ferrando A, Balbin M, Pendas A, Vizoso F, Velasco G, Lopez-Otin C . Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum Genet. 1996; 97(1):91-4. DOI: 10.1007/BF00218840. View

Vitagliano D, Carlomagno F, Motti M, Viglietto G, Nikiforov Y, Nikiforova M . Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells. Cancer Res. 2004; 64(11):3823-9. DOI: 10.1158/0008-5472.CAN-03-3918. View

Chang B, Zheng S, Isaacs S, Wiley K, Turner A, Li G . A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res. 2004; 64(6):1997-9. DOI: 10.1158/0008-5472.can-03-2340. View

Baldassarre G, Bruni P, Boccia A, Salvatore G, Melillo R, Motti M . Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1). Oncogene. 2002; 21(11):1739-49. DOI: 10.1038/sj.onc.1205226. View

Porter P, Malone K, Heagerty P, Alexander G, Gatti L, Firpo E . Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997; 3(2):222-5. DOI: 10.1038/nm0297-222. View

Thakker R . Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2013; 386(1-2):2-15. PMC: 4082531. DOI: 10.1016/j.mce.2013.08.002. View

Fero M, Randel E, Gurley K, Roberts J, Kemp C . The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998; 396(6707):177-80. PMC: 5395202. DOI: 10.1038/24179. View

10.

Beltran H, Tomlins S, Aparicio A, Arora V, Rickman D, Ayala G . Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014; 20(11):2846-50. PMC: 4040316. DOI: 10.1158/1078-0432.CCR-13-3309. View

11.

Baca S, Prandi D, Lawrence M, Mosquera J, Romanel A, Drier Y . Punctuated evolution of prostate cancer genomes. Cell. 2013; 153(3):666-77. PMC: 3690918. DOI: 10.1016/j.cell.2013.03.021. View

12.

Karnik S, Hughes C, Gu X, Rozenblatt-Rosen O, McLean G, Xiong Y . Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005; 102(41):14659-64. PMC: 1253549. DOI: 10.1073/pnas.0503484102. View

13.

Kossatz U, Vervoorts J, Nickeleit I, Sundberg H, Arthur J, Manns M . C-terminal phosphorylation controls the stability and function of p27kip1. EMBO J. 2006; 25(21):5159-70. PMC: 1630410. DOI: 10.1038/sj.emboj.7601388. View

14.

Thakker R . Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010; 24(3):355-70. DOI: 10.1016/j.beem.2010.07.003. View

15.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

16.

Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

17.

Baldassarre G, Belletti B, Nicoloso M, Schiappacassi M, Vecchione A, Spessotto P . p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell. 2005; 7(1):51-63. DOI: 10.1016/j.ccr.2004.11.025. View

18.

Fritz A, Walch A, Piotrowska K, Rosemann M, Schaffer E, Weber K . Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002; 62(11):3048-51. View

19.

Crona J, Gustavsson T, Norlen O, Edfeldt K, Akerstrom T, Westin G . Somatic Mutations and Genetic Heterogeneity at the CDKN1B Locus in Small Intestinal Neuroendocrine Tumors. Ann Surg Oncol. 2015; 22 Suppl 3:S1428-35. DOI: 10.1245/s10434-014-4351-9. View

20.

Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, HORII I . Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 1996; 85(5):707-20. DOI: 10.1016/s0092-8674(00)81237-4. View